{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:15:52Z","timestamp":1783332952668,"version":"3.54.6"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI150597"],"award-info":[{"award-number":["R01AI150597"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI125640"],"award-info":[{"award-number":["R01AI125640"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI175498"],"award-info":[{"award-number":["R01AI175498"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI197040"],"award-info":[{"award-number":["R21AI197040"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00785-x","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:14:47Z","timestamp":1778696087000},"page":"567-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders"],"prefix":"10.1007","volume":"40","author":[{"given":"Justin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacim","family":"Kerrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotam","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"4","key":"785_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178722","volume":"135","author":"AH Abend","year":"2024","unstructured":"Abend AH, He I, Bahroos N, et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J Clin Invest. 2024;135(4):e178722. https:\/\/doi.org\/10.1172\/JCI178722.","journal-title":"J Clin Invest"},{"key":"785_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/7854_2016_7","volume":"31","author":"CR Pryce","year":"2017","unstructured":"Pryce CR, Fontana A. Depression in autoimmune diseases. Curr Top Behav Neurosci. 2017;31:139\u201354. https:\/\/doi.org\/10.1007\/7854_2016_7.","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"785_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8(1):235. https:\/\/doi.org\/10.1038\/s41392-023-01471-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"31","key":"785_CR4","doi-asserted-by":"publisher","first-page":"51936","DOI":"10.18632\/oncotarget.17232","volume":"8","author":"H Arasanz","year":"2017","unstructured":"Arasanz H, Gato-Ca\u00f1as M, Zuazo M, et al. PD1 signal transduction pathways in T cells. Oncotarget. 2017;8(31):51936\u201345. https:\/\/doi.org\/10.18632\/oncotarget.17232.","journal-title":"Oncotarget"},{"issue":"9","key":"785_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.20021910","volume":"197","author":"JM Curtsinger","year":"2003","unstructured":"Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003;197(9):1141\u201351. https:\/\/doi.org\/10.1084\/jem.20021910.","journal-title":"J Exp Med"},{"issue":"4","key":"785_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1615\/critrevimmunol.v24.i4.10","volume":"24","author":"Y Zha","year":"2004","unstructured":"Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004;24(4):229\u201337. https:\/\/doi.org\/10.1615\/critrevimmunol.v24.i4.10.","journal-title":"Crit Rev Immunol"},{"issue":"11","key":"785_CR7","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05481.x.","journal-title":"EMBO J"},{"issue":"3","key":"785_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"785_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337\u201347. https:\/\/doi.org\/10.1016\/s1074-7613(04)00051-2.","journal-title":"Immunity"},{"issue":"2","key":"785_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945\u201354. https:\/\/doi.org\/10.4049\/jimmunol.173.2.945.","journal-title":"J Immunol"},{"issue":"1","key":"785_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1006\/excr.1997.3493","volume":"232","author":"R Vibhakar","year":"1997","unstructured":"Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res. 1997;232(1):25\u20138. https:\/\/doi.org\/10.1006\/excr.1997.3493.","journal-title":"Exp Cell Res"},{"issue":"3","key":"785_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138. https:\/\/doi.org\/10.1038\/85330.","journal-title":"Nat Immunol"},{"issue":"1","key":"785_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22965-9","volume":"12","author":"K Li","year":"2021","unstructured":"Li K, Yuan Z, Lyu J, et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat Commun. 2021;12(1):2746. https:\/\/doi.org\/10.1038\/s41467-021-22965-9.","journal-title":"Nat Commun"},{"issue":"1\u20133","key":"785_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"KA Sheppard","year":"2004","unstructured":"Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1\u20133):37\u201341. https:\/\/doi.org\/10.1016\/j.febslet.2004.07.083.","journal-title":"FEBS Lett"},{"issue":"6","key":"785_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317. https:\/\/doi.org\/10.1084\/jem.20112741.","journal-title":"J Exp Med"},{"issue":"1","key":"785_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-0845-0","volume":"3","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Duke-Cohan JS, Chaudhri A, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3(1):128. https:\/\/doi.org\/10.1038\/s42003-020-0845-0.","journal-title":"Commun Biol"},{"issue":"24","key":"785_CR17","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting Src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866\u201371. https:\/\/doi.org\/10.1073\/pnas.231486598.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"785_CR18","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1073\/pnas.1710437115","volume":"115","author":"M Peled","year":"2018","unstructured":"Peled M, Tocheva AS, Sandigursky S, et al. Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proc Natl Acad Sci U S A. 2018;115(3):E468\u201377. https:\/\/doi.org\/10.1073\/pnas.1710437115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6332","key":"785_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428\u201333. https:\/\/doi.org\/10.1126\/science.aaf1292.","journal-title":"Science"},{"issue":"19","key":"785_CR20","doi-asserted-by":"publisher","first-page":"16520","DOI":"10.1074\/jbc.M210572200","volume":"278","author":"Y Chen","year":"2003","unstructured":"Chen Y, Wen R, Yang S, et al. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem. 2003;278(19):16520\u20137. https:\/\/doi.org\/10.1074\/jbc.M210572200.","journal-title":"J Biol Chem"},{"issue":"3","key":"785_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12571","volume":"52","author":"R Zhao","year":"2019","unstructured":"Zhao R, Song Y, Wang Y, et al. PD-1\/PD-L1 blockade rescues exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K\/Akt\/mTOR signalling pathway. Cell Prolif. 2019;52(3):e12571. https:\/\/doi.org\/10.1111\/cpr.12571.","journal-title":"Cell Prolif"},{"issue":"230","key":"785_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2002796","volume":"5","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46. https:\/\/doi.org\/10.1126\/scisignal.2002796.","journal-title":"Sci Signal"},{"issue":"12","key":"785_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41422-023-00890-4","volume":"33","author":"R Liu","year":"2023","unstructured":"Liu R, Zeng LW, Li HF, et al. PD-1 signaling negatively regulates the common cytokine receptor \u03b3 chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity. Cell Res. 2023;33(12):923\u201339. https:\/\/doi.org\/10.1038\/s41422-023-00890-4.","journal-title":"Cell Res"},{"key":"785_CR24","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.3389\/fimmu.2019.02430","volume":"10","author":"Q Liu","year":"2019","unstructured":"Liu Q, Ou Q, Shen L, et al. BATF potentially mediates negative regulation of PD-1\/PD-Ls pathway on T cell functions in Mycobacterium tuberculosis infection. Front Immunol. 2019;10:2430. https:\/\/doi.org\/10.3389\/fimmu.2019.02430.","journal-title":"Front Immunol"},{"issue":"27","key":"785_CR25","doi-asserted-by":"publisher","first-page":"E248","DOI":"10.1073\/pnas.1305394110","volume":"110","author":"F Wei","year":"2013","unstructured":"Wei F, Zhong S, Ma Z, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A. 2013;110(27):E248\u20139. https:\/\/doi.org\/10.1073\/pnas.1305394110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"785_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009063","volume":"12","author":"LA Emens","year":"2024","unstructured":"Emens LA, Romero PJ, Anderson AC, et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer. 2024;12(6):e009063. https:\/\/doi.org\/10.1136\/jitc-2024-009063.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"785_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.1701044","volume":"200","author":"MW LaFleur","year":"2018","unstructured":"LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 2018;200(2):375\u201383. https:\/\/doi.org\/10.4049\/jimmunol.1701044.","journal-title":"J Immunol"},{"key":"785_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"785_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410\u20136. https:\/\/doi.org\/10.7150\/jca.17144.","journal-title":"J Cancer"},{"issue":"5","key":"785_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1571892.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"785_CR31","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/medicina5811157","volume":"58","author":"FK Alkholifi","year":"2022","unstructured":"Alkholifi FK, Alsaffar RM. Dostarlimab an inhibitor of PD-1\/PD-L1: a new paradigm for the treatment of cancer. Medicina (Kaunas). 2022;58(11):1572. https:\/\/doi.org\/10.3390\/medicina5811157.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"785_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00262-024-03635-3","volume":"73","author":"N Rajasekaran","year":"2024","unstructured":"Rajasekaran N, Wang X, Ravindranathan S, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024;73(3):60. https:\/\/doi.org\/10.1007\/s00262-024-03635-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"10495","key":"785_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","volume":"405","author":"S Rao","year":"2025","unstructured":"Rao S, Samalin-Scalzi E, Evesque L, et al. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial. Lancet. 2025;405(10495):2144\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(25)00631-2.","journal-title":"Lancet"},{"key":"785_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296","volume":"29","author":"L Zhang","year":"2022","unstructured":"Zhang L, Geng Z, Hao B, Geng Q. Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Cancer Control. 2022;29:10732748221111296. https:\/\/doi.org\/10.1177\/10732748221111296.","journal-title":"Cancer Control"},{"issue":"10","key":"785_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007637","volume":"11","author":"P Clingan","year":"2023","unstructured":"Clingan P, Ladwa R, Brungs D, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007637. https:\/\/doi.org\/10.1136\/jitc-2023-007637.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"785_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5367.","journal-title":"JAMA Oncol"},{"key":"785_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252215","volume":"13","author":"E Sebesty\u00e9n","year":"2023","unstructured":"Sebesty\u00e9n E, Major N, Bodoki L, et al. Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience. Front Oncol. 2023;13:1252215. https:\/\/doi.org\/10.3389\/fonc.2023.1252215.","journal-title":"Front Oncol"},{"key":"785_CR38","unstructured":"Postow M, Johnson DB. Overview of toxicities associated with immune checkpoint inhibitors. UpToDate. Available from: https:\/\/www.uptodate.com\/contents\/overview-of-toxicities-associated-with-immune-checkpoint-inhibitors?topicRef=128565&source=see_link. [Accessed 2 May 2026]."},{"issue":"17","key":"785_CR39","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"785_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardiooncology primer. JACC CardioOncol. 2021;3(1):35\u201347. https:\/\/doi.org\/10.1016\/j.jaccao.2020.11.012.","journal-title":"JACC CardioOncol"},{"key":"785_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.885001","volume":"10","author":"C Lin","year":"2022","unstructured":"Lin C, Li X, Qiu Y, Chen Z, Liu J. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. Front Public Health. 2022;10:885001. https:\/\/doi.org\/10.3389\/fpubh.2022.885001.","journal-title":"Front Public Health"},{"issue":"10","key":"785_CR42","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21(10):1230\u201340. https:\/\/doi.org\/10.1634\/theoncologist.2016-0055.","journal-title":"Oncologist"},{"issue":"12","key":"785_CR43","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"key":"785_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573492","volume":"16","author":"R Kondo","year":"2025","unstructured":"Kondo R, Kondo K, Nabeshima K, et al. PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution. Front Immunol. 2025;16:1573492. https:\/\/doi.org\/10.3389\/fimmu.2025.1573492.","journal-title":"Front Immunol"},{"key":"785_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x.","journal-title":"Immunol Rev"},{"issue":"2","key":"785_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351. https:\/\/doi.org\/10.1016\/s1074-7613(00)80089-8.","journal-title":"Immunity"},{"issue":"5502","key":"785_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322. https:\/\/doi.org\/10.1126\/science.291.5502.319.","journal-title":"Science"},{"issue":"3","key":"785_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/ni1165","volume":"6","author":"HC Probst","year":"2005","unstructured":"Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005;6(3):280\u20136. https:\/\/doi.org\/10.1038\/ni1165.","journal-title":"Nat Immunol"},{"issue":"4","key":"785_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195\u2013201. https:\/\/doi.org\/10.1016\/j.it.2006.02.001.","journal-title":"Trends Immunol"},{"issue":"8","key":"785_CR50","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.4049\/jimmunol.181.8.5313","volume":"181","author":"BH Koehn","year":"2008","unstructured":"Koehn BH, Ford ML, Ferrer IR, et al. PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J Immunol. 2008;181(8):5313\u201322. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5313.","journal-title":"J Immunol"},{"issue":"12","key":"785_CR51","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1084\/jem.20061577","volume":"203","author":"BT Fife","year":"2006","unstructured":"Fife BT, Guleria I, Gubbels Bupp M, et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006;203(12):2737\u201347. https:\/\/doi.org\/10.1084\/jem.20061577.","journal-title":"J Exp Med"},{"key":"785_CR52","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00662.x.","journal-title":"Immunol Rev"},{"issue":"1","key":"785_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. https:\/\/doi.org\/10.1080\/2162402X.2017.1364828.","journal-title":"Oncoimmunology"},{"key":"785_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102266","volume":"80","author":"FW Miller","year":"2023","unstructured":"Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. https:\/\/doi.org\/10.1016\/j.coi.2022.102266.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"785_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19290-3","volume":"24","author":"M Zhao","year":"2024","unstructured":"Zhao M, Zhai H, Li H, et al. Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15-39 years): an analysis based on the global burden of disease study 2021. BMC Public Health. 2024;24(1):1800. https:\/\/doi.org\/10.1186\/s12889-024-19290-3.","journal-title":"BMC Public Health"},{"issue":"9","key":"785_CR56","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","volume":"27","author":"M Ogishi","year":"2021","unstructured":"Ogishi M, Yang R, Aytekin C, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med. 2021;27(9):1646\u201354. https:\/\/doi.org\/10.1038\/s41591-021-01388-5.","journal-title":"Nat Med"},{"issue":"6","key":"785_CR57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231704","volume":"221","author":"MB Johnson","year":"2024","unstructured":"Johnson MB, Ogishi M, Domingo-Vila C, et al. Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency. J Exp Med. 2024;221(6):e20231704. https:\/\/doi.org\/10.1084\/jem.20231704.","journal-title":"J Exp Med"},{"issue":"3","key":"785_CR58","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/art.20040","volume":"50","author":"SC Lin","year":"2004","unstructured":"Lin SC, Yen JH, Tsai JJ, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 2004;50(3):770\u20135. https:\/\/doi.org\/10.1002\/art.20040.","journal-title":"Arthritis Rheum"},{"key":"785_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jneuroim.2017.02.006","volume":"305","author":"E Pawlak-Adamska","year":"2017","unstructured":"Pawlak-Adamska E, Nowak O, Karabon L, et al. PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. J Neuroimmunol. 2017;305:115\u201327. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.02.006.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"785_CR60","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng1020","volume":"32","author":"L Prokunina","year":"2002","unstructured":"Prokunina L, Castillejo-L\u00f3pez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002;32(4):666\u20139. https:\/\/doi.org\/10.1038\/ng1020.","journal-title":"Nat Genet"},{"issue":"5","key":"785_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","volume":"4","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0123.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"785_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102596","volume":"19","author":"B Terrier","year":"2020","unstructured":"Terrier B, Humbert S, Preta LH, et al. Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmun Rev. 2020;19(8):102596. https:\/\/doi.org\/10.1016\/j.autrev.2020.102596.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"785_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2013.183","volume":"10","author":"ML Ford","year":"2014","unstructured":"Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014;10(1):14\u201324. https:\/\/doi.org\/10.1038\/nrneph.2013.183.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"785_CR64","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-23-1014","volume":"30","author":"SH Lim","year":"2024","unstructured":"Lim SH, Beers SA, Al-Shamkhani A, Cragg MS. Agonist antibodies for cancer immunotherapy: history, hopes, and challenges. Clin Cancer Res. 2024;30(9):1712\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1014.","journal-title":"Clin Cancer Res"},{"key":"785_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.015","volume":"158","author":"CJ Jordan","year":"2019","unstructured":"Jordan CJ, Cao J, Newman AH, Xi ZX. Progress in agonist therapy for substance use disorders: lessons learned from methadone and buprenorphine. Neuropharmacology. 2019;158:107609. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.015.","journal-title":"Neuropharmacology"},{"issue":"7","key":"785_CR66","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/art.27500","volume":"62","author":"AP Raptopoulou","year":"2010","unstructured":"Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62(7):1870\u201380. https:\/\/doi.org\/10.1002\/art.27500.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"785_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/gutjnl-2014-307311","volume":"64","author":"MY Song","year":"2015","unstructured":"Song MY, Hong CP, Park SJ, et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut. 2015;64(2):260\u201371. https:\/\/doi.org\/10.1136\/gutjnl-2014-307311.","journal-title":"Gut"},{"key":"785_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2015.10.006","volume":"162","author":"H Zhou","year":"2016","unstructured":"Zhou H, Xiong L, Wang Y, et al. Treatment of murine lupus with PD-LIg. Clin Immunol. 2016;162:1\u20138. https:\/\/doi.org\/10.1016\/j.clim.2015.10.006.","journal-title":"Clin Immunol"},{"issue":"20","key":"785_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152468","volume":"6","author":"AP Curnock","year":"2021","unstructured":"Curnock AP, Bossi G, Kumaran J, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6(20):e152468. https:\/\/doi.org\/10.1172\/jci.insight.152468.","journal-title":"JCI Insight"},{"issue":"4","key":"785_CR70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","volume":"3","author":"P Zhao","year":"2019","unstructured":"Zhao P, Wang P, Dong S, et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng. 2019;3(4):292\u2013305. https:\/\/doi.org\/10.1038\/s41551-019-0360-0.","journal-title":"Nat Biomed Eng"},{"issue":"17","key":"785_CR71","doi-asserted-by":"publisher","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","volume":"288","author":"X Cheng","year":"2013","unstructured":"Cheng X, Veverka V, Radhakrishnan A, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem. 2013;288(17):11771\u201385. https:\/\/doi.org\/10.1074\/jbc.M112.448126.","journal-title":"J Biol Chem"},{"issue":"30","key":"785_CR72","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.0804453105","volume":"105","author":"E L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","unstructured":"L\u00e1z\u00e1r-Moln\u00e1r E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A. 2008;105(30):10483\u20138. https:\/\/doi.org\/10.1073\/pnas.0804453105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"785_CR73","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116\u201326. https:\/\/doi.org\/10.1038\/nri727.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"785_CR74","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1006\/geno.1994.1562","volume":"23","author":"T Shinohara","year":"1994","unstructured":"Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 1994;23(3):704\u20136. https:\/\/doi.org\/10.1006\/geno.1994.1562.","journal-title":"Genomics"},{"issue":"43","key":"785_CR75","doi-asserted-by":"publisher","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","volume":"271","author":"JL Greene","year":"1996","unstructured":"Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271(43):26762\u201371. https:\/\/doi.org\/10.1074\/jbc.271.43.26762.","journal-title":"J Biol Chem"},{"issue":"6716","key":"785_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/16717","volume":"397","author":"A Hutloff","year":"1999","unstructured":"Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263\u20136. https:\/\/doi.org\/10.1038\/16717.","journal-title":"Nature"},{"issue":"25","key":"785_CR77","doi-asserted-by":"publisher","first-page":"15417","DOI":"10.1074\/jbc.270.25.15417","volume":"270","author":"PS Linsley","year":"1995","unstructured":"Linsley PS, Nadler SG, Bajorath J, et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4): a disulfide-linked homodimer binds two CD86 molecules. J Biol Chem. 1995;270(25):15417\u201324. https:\/\/doi.org\/10.1074\/jbc.270.25.15417.","journal-title":"J Biol Chem"},{"issue":"93","key":"785_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade6256","volume":"9","author":"EA Philips","year":"2024","unstructured":"Philips EA, Liu J, Kvalvaag A, et al. Transmembrane domain-driven PD-1 dimers mediate T cell inhibition. Sci Immunol. 2024;9(93):eade6256. https:\/\/doi.org\/10.1126\/sciimmunol.ade6256.","journal-title":"Sci Immunol"},{"key":"785_CR79","doi-asserted-by":"publisher","unstructured":"Anderson SM, Choi J, Cushman EM, Leander M, Raman S, Senes A. High-throughput discovery of transmembrane helix dimers from human single-pass membrane proteins with TOXGREEN sort-seq. Preprint. bioRxiv. 2025;2025.04.22.650048. https:\/\/doi.org\/10.1101\/2025.04.22.650048.","DOI":"10.1101\/2025.04.22.650048"},{"issue":"11","key":"785_CR80","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.28.591549","volume":"43","author":"EB Saad","year":"2024","unstructured":"Saad EB, Oroya A, Anto NP, Bachais M, Rudd CE. PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity. Cell Rep. 2024;43(11):114907. https:\/\/doi.org\/10.1101\/2024.04.28.591549.","journal-title":"Cell Rep"},{"issue":"29","key":"785_CR81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102164118","volume":"118","author":"CM Bryan","year":"2021","unstructured":"Bryan CM, Rocklin GJ, Bick MJ, et al. Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci U S A. 2021;118(29):e2102164118. https:\/\/doi.org\/10.1073\/pnas.2102164118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"785_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103339","volume":"149","author":"Y Feng","year":"2024","unstructured":"Feng Y, Deyanat-Yazdi G, Newburn K, et al. PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation: therapeutic implications for autoimmunity. J Autoimmun. 2024;149:103339. https:\/\/doi.org\/10.1016\/j.jaut.2024.103339.","journal-title":"J Autoimmun"},{"issue":"3","key":"785_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200839","volume":"32","author":"LY Hao","year":"2024","unstructured":"Hao LY, Lerrer S, Paiola M, et al. Exclusion of PD-1 from the immune synapse: a novel strategy to modulate T cell function. Mol Ther Oncol. 2024;32(3):200839. https:\/\/doi.org\/10.1016\/j.omton.2024.200839.","journal-title":"Mol Ther Oncol"},{"key":"785_CR84","doi-asserted-by":"publisher","unstructured":"Ma Z, Hellweg L, Elledge SK, et al. Synthetic signaling platform uncovers and rewires cellular responses to PD-1 perturbation. Preprint. bioRxiv. 2025;2025.10.01.679874. https:\/\/doi.org\/10.1101\/2025.10.01.679874.","DOI":"10.1101\/2025.10.01.679874"},{"issue":"11","key":"785_CR85","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1016\/j.celrep.2019.05.027","volume":"27","author":"P Zhang","year":"2019","unstructured":"Zhang P, Tu GH, Wei J, et al. Ligand-blocking and membrane-proximal domain targeting anti-OX40 antibodies mediate potent T cell-stimulatory and anti-tumor activity. Cell Rep. 2019;27(11):3117-23.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.027.","journal-title":"Cell Rep"},{"issue":"1","key":"785_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03182-6","volume":"5","author":"F Heckel","year":"2022","unstructured":"Heckel F, Turaj AH, Fisher H, et al. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun Biol. 2022;5(1):229. https:\/\/doi.org\/10.1038\/s42003-022-03182-6.","journal-title":"Commun Biol"},{"issue":"4","key":"785_CR87","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ccell.2018.02.009","volume":"33","author":"X Yu","year":"2018","unstructured":"Yu X, Chan HTC, Orr CM, et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 2018;33(4):664-75.e4. https:\/\/doi.org\/10.1016\/j.ccell.2018.02.009.","journal-title":"Cancer Cell"},{"issue":"79","key":"785_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4947","volume":"8","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Tajima M, Tokumaru Y, et al. Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Sci Immunol. 2023;8(79):eadd4947. https:\/\/doi.org\/10.1126\/sciimmunol.add4947.","journal-title":"Sci Immunol"},{"key":"785_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1631929","volume":"16","author":"L Liu","year":"2025","unstructured":"Liu L, Takashima S, Tokumaru Y, Ikuta N, Nakajima Y, Ohta A. Identification of anti-mouse PD-1 agonist antibodies that inhibit T cell activation. Front Immunol. 2025;16:1631929. https:\/\/doi.org\/10.3389\/fimmu.2025.1631929.","journal-title":"Front Immunol"},{"issue":"1","key":"785_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2236740","volume":"15","author":"M Jiang","year":"2023","unstructured":"Jiang M, Liu M, Liu G, Ma J, Zhang L, Wang S. Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1. MAbs. 2023;15(1):2236740. https:\/\/doi.org\/10.1080\/19420862.2023.2236740.","journal-title":"MAbs"},{"issue":"9","key":"785_CR91","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/fon.15.52","volume":"11","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11(9):1307\u201326. https:\/\/doi.org\/10.2217\/fon.15.52.","journal-title":"Future Oncol"},{"issue":"7948","key":"785_CR92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-022-05673-2","volume":"614","author":"X Yu","year":"2023","unstructured":"Yu X, Orr CM, Chan HTC, et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 2023;614(7948):539\u201347. https:\/\/doi.org\/10.1038\/s41586-022-05673-2.","journal-title":"Nature"},{"issue":"1","key":"785_CR93","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2088454","volume":"14","author":"SC Cowles","year":"2022","unstructured":"Cowles SC, Sheen A, Santollani L, et al. An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy. MAbs. 2022;14(1):2088454. https:\/\/doi.org\/10.1080\/19420862.2022.2088454.","journal-title":"MAbs"},{"issue":"7","key":"785_CR94","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/cdd.2011.208","volume":"19","author":"M Chodorge","year":"2012","unstructured":"Chodorge M, Z\u00fcger S, Stirnimann C, et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ. 2012;19(7):1187\u201395. https:\/\/doi.org\/10.1038\/cdd.2011.208.","journal-title":"Cell Death Differ"},{"issue":"5","key":"785_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051435","volume":"19","author":"\u0141 Opali\u0144ski","year":"2018","unstructured":"Opali\u0144ski \u0141, Szymczyk J, Szczepara M, et al. High affinity promotes internalization of engineered antibodies targeting FGFR1. Int J Mol Sci. 2018;19(5):1435. https:\/\/doi.org\/10.3390\/ijms19051435.","journal-title":"Int J Mol Sci"},{"key":"785_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00811","volume":"10","author":"S Ben Mkaddem","year":"2019","unstructured":"Ben Mkaddem S, Benhamou M, Monteiro RC. Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front Immunol. 2019;10:811. https:\/\/doi.org\/10.3389\/fimmu.2019.00811.","journal-title":"Front Immunol"},{"issue":"8","key":"785_CR97","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nri856","volume":"2","author":"T Takai","year":"2002","unstructured":"Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2(8):580\u201392. https:\/\/doi.org\/10.1038\/nri856.","journal-title":"Nat Rev Immunol"},{"key":"785_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.coi.2016.03.002","volume":"40","author":"RJ Brezski","year":"2016","unstructured":"Brezski RJ, Georgiou G. Immunoglobulin isotype knowledge and application to Fc engineering. Curr Opin Immunol. 2016;40:62\u20139. https:\/\/doi.org\/10.1016\/j.coi.2016.03.002.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"785_CR99","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1084\/jem.173.6.1483","volume":"173","author":"SM Canfield","year":"1991","unstructured":"Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med. 1991;173(6):1483\u201391. https:\/\/doi.org\/10.1084\/jem.173.6.1483.","journal-title":"J Exp Med"},{"issue":"1","key":"785_CR100","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34\u201347. https:\/\/doi.org\/10.1038\/nri2206.","journal-title":"Nat Rev Immunol"},{"key":"785_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00079","volume":"6","author":"LT Vogelpoel","year":"2015","unstructured":"Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79. https:\/\/doi.org\/10.3389\/fimmu.2015.00079.","journal-title":"Front Immunol"},{"key":"785_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00674","volume":"5","author":"SQ Nagelkerke","year":"2015","unstructured":"Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2015;5:674. https:\/\/doi.org\/10.3389\/fimmu.2014.00674.","journal-title":"Front Immunol"},{"issue":"10","key":"785_CR103","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1172\/JCI24772","volume":"115","author":"AM Boruchov","year":"2005","unstructured":"Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005;115(10):2914\u201323. https:\/\/doi.org\/10.1172\/JCI24772.","journal-title":"J Clin Invest"},{"issue":"1","key":"785_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09434-0","volume":"10","author":"M Esp\u00e9li","year":"2019","unstructured":"Esp\u00e9li M, Bashford-Rogers R, Sowerby JM, et al. Fc\u03b3RIIb differentially regulates pre-immune and germinal center B cell tolerance in mouse and human. Nat Commun. 2019;10(1):1970. https:\/\/doi.org\/10.1038\/s41467-019-09434-0.","journal-title":"Nat Commun"},{"issue":"6","key":"785_CR105","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","volume":"29","author":"R Dahan","year":"2016","unstructured":"Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective Fc\u03b3R engagement. Cancer Cell. 2016;29(6):820\u201331. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.001.","journal-title":"Cancer Cell"},{"key":"785_CR106","unstructured":"Liew D. Where are we at with PD-1 agonism? RheumNow. Published 2025 October 30. Available from: https:\/\/rheumnow.com\/news\/where-are-we-pd-1-agonism. [Accessed 10 Mar 2026]."},{"key":"785_CR107","unstructured":"Masson G. Gilead pays out $405M for a chance to compete with Eli Lilly\u2019s BTLA program. August 4, 2022. Available from: https:\/\/www.fiercebiotech.com\/biotech\/gilead-pays-out-405m-mirobio-chances-compete-lillys-btla-program. [Accessed 10 Mar 2026]."},{"issue":"20","key":"785_CR108","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"J Tuttle","year":"2023","unstructured":"Tuttle J, Drescher E, Sim\u00f3n-Campos JA, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2209856.","journal-title":"N Engl J Med"},{"key":"785_CR109","unstructured":"Tuttle J, Griffing K, Genovese M, et al. A phase 2b dose-ranging study of peresolimab for adults with RA [abstract]. Arthritis Rheumatol. 2025;77(Suppl. 9). Available from: https:\/\/acrabstracts.org\/abstract\/a-phase-2b-dose-ranging-study-of-peresolimab-for-adults-with-ra\/. [Accessed 2 May 2026]."},{"key":"785_CR110","unstructured":"Manasson J, Panduro M, Cianci M, et al. S-4321, a novel dual-cell bidirectional PD-1:Fc\u03b3RIIb selective agonist antibody for the treatment of autoimmune disease [abstract]. Arthritis Rheumatol. 2024;76(Suppl. 9). Available from: https:\/\/acrabstracts.org\/abstract\/s-4321-a-novel-dual-cell-bidirectional-pd-1fc%ce%b3riib-selective-agonist-antibody-for-the-treatment-of-autoimmune-disease\/. [Accessed 2 May 2026]."},{"key":"785_CR111","doi-asserted-by":"crossref","unstructured":"Manasson J, Cianci M, Borah M, et al. S-4321, a novel dual-cell bifunctional PD-1:Fc\u03b3RIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo [abstract]. Arthritis Rheumatol. 2025;77(Suppl. 9). Available from: https:\/\/acrabstracts.org\/abstract\/s-4321-a-novel-dual-cell-bifunctional-pd-1fc%ce%b3riib-selective-agonist-antibody-for-autoimmune-disease-maintains-expression-of-pd-1-on-target-cells-and-enhances-inhibitory-receptor-expression-on\/.\u00a0[Accessed 2 May 2026].","DOI":"10.1016\/S0016-5085(26)06565-0"},{"issue":"Suppl_1","key":"785_CR112","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0296","volume":"18","author":"S Parmley","year":"2024","unstructured":"Parmley S, Szylyk B, Frank R, et al. P166 Optimizing PD-1 agonist signaling with membrane proximal binding of rosnilimab, a clinical stage PD-1 agonist IgG1 antibody. J Crohns Colitis. 2024;18(Suppl_1):i466. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0296.","journal-title":"J Crohns Colitis"},{"key":"785_CR113","unstructured":"Graf J, Archer A, Kovalenko S, et al. Rosnilimab, a selective and potent depleter of pathogenic T cells, demonstrates efficacy, safety, and translational proof of mechanism in a rheumatoid arthritis phase 2B trial [abstract]. Arthritis Rheumatol. 2025;77(Suppl. 9). Available from: https:\/\/acrabstracts.org\/abstract\/rosnilimab-a-selective-and-potent-depleter-of-pathogenic-t-cells-demonstrates-efficacy-safety-and-translational-proof-of-mechanism-in-a-rheumatoid-arthritis-phase-2b-trial\/.\u00a0[Accessed 2 May 2026]."},{"key":"785_CR114","unstructured":"AnaptysBio Inc. Anaptys announces phase 2 trial of rosnilimab did not meet primary or secondary endpoints at week 12 in moderate-to-severe ulcerative colitis. Published 2025. Available from: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptys-announces-phase-2-trial-rosnilimab-did-not-meet-primary. [Accessed 10 Mar 2026]."},{"key":"785_CR115","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251385857","volume":"17","author":"ITC Ling","year":"2025","unstructured":"Ling ITC, Marciniak SJ, Clarke SH, et al. Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study. Ther Adv Musculoskelet Dis. 2025;17:1759720X251385857. https:\/\/doi.org\/10.1177\/1759720X251385857.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"785_CR116","unstructured":"Janssen Research and Development. A phase 2a, multi-center, randomized, double-blind, placebo-controlled, proof of concept study to evaluate the efficacy, safety and tolerability of JNJ-67484703 in participants with atopic dermatitis. Clinicaltrialsregister.eu. Published 2022. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-001528-14\/results. [Accessed 10 Mar 2026]."},{"key":"785_CR117","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ard.2025.05.482","volume":"84","author":"BA Fisher","year":"2025","unstructured":"Fisher BA, van Turner JD, et al. POS0094-Pharmacodynamic activity of JNJ-67484703 in rheumatoid arthritis, ulcerative colitis and Sjogren\u2019s disease (PARIS): results of a phase II proof of biology trial. Ann Rheum Dis. 2025;84:389\u201390. https:\/\/doi.org\/10.1016\/j.ard.2025.05.482.","journal-title":"Ann Rheum Dis"},{"key":"785_CR118","unstructured":"GenSci. NMPA approves the PD-1 agonist GenSci120 for clinical trials commencement. GenSci. Published January 15, 2025. Available from: https:\/\/www.genscigroup.com\/en\/news\/media\/164. [Accessed 10 Mar 2026]."},{"issue":"1","key":"785_CR119","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2624881","volume":"18","author":"W Jiang","year":"2026","unstructured":"Jiang W, Li L, Xue W, et al. Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases. MAbs. 2026;18(1):2624881. https:\/\/doi.org\/10.1080\/19420862.2026.2624881.","journal-title":"MAbs"},{"key":"785_CR120","unstructured":"Bratulic A. Merck & Co. to buy Pandion for $1.85 billion, gaining autoimmune drug pipeline. Firstwordpharma.com. Published 2025. Available from: https:\/\/firstwordpharma.com\/story\/5233861. [Accessed 10 Mar 2026]."},{"key":"785_CR121","unstructured":"Meiji Seika Pharma Co. A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe. News release. Meiji Seika Pharma Co. Published 2023. Available from: https:\/\/www.meiji.com\/global\/news\/2023\/pdf\/230116_01.pdf. [Accessed 10 Mar 2026]."},{"key":"785_CR122","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2023.02.007","volume":"156","author":"D White","year":"2023","unstructured":"White D, Cote-Martin A, Bleck M, et al. Programmed cell death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. Mol Immunol. 2023;156:31\u20138. https:\/\/doi.org\/10.1016\/j.molimm.2023.02.007.","journal-title":"Mol Immunol"},{"key":"785_CR123","doi-asserted-by":"publisher","unstructured":"Lazar-Molnar E, Ramagopal UA, Nathenson SG, Almo SC. Crystal structure of the extracellular domain of human PD-1. Protein Data Bank (PDB). Published 2012. PDB ID: 3RRQ. https:\/\/doi.org\/10.2210\/pdb3rrq\/pdb.","DOI":"10.2210\/pdb3rrq\/pdb"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00785-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00785-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00785-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:37:54Z","timestamp":1783330674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00785-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00785-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"27 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We acknowledge support from the following grants: National\u00a0Institutes of Health grants R01AI150597 [AM], R01AI125640 [AM], R21AI197040 [AM], and R01AI175498 [AM].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Justin Zhong, Ruijiang Song, Nacim Kerrouche, Xinyu Yu, Yotam Levin, and Adam Mor have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JZ and AM were responsible for the conceptualization of the manuscript. JZ wrote the initial draft of the manuscript. JZ, NK, RS, and AM provided critical edits to the initial draft. JZ, XY, YL, and AM contributed to critical revisions after initial submission. JZ, XY, and AM contributed to the creation and revision of the figures. JZ contributed to creating the table. AM secured funding for this manuscript. All authors have read and approved the final version of the manuscript, and all authors agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}